Results 1 to 10 of about 1,626,953 (426)
PTK2 and PTPN11 expression in myelodysplastic syndromes [PDF]
Clinics, 2013 OBJECTIVE: The aim of this study was to evaluate the expression of protein tyrosine kinase 2 and protein tyrosine phosphatase non-receptor type 11, which respectively encode focal adhesion kinase protein and src homology 2 domain-containing protein ...
Mariana Lazarini +6 more
doaj +5 more sources
The tyrosine kinase Csk dimerizes through Its SH3 domain. [PDF]
PLoS ONE, 2009 The Src family kinases possess two sites of tyrosine phosphorylation that are critical to the regulation of kinase activity. Autophosphorylation on an activation loop tyrosine residue (Tyr 416 in commonly used chicken c-Src numbering) increases catalytic
Nicholas M Levinson +2 more
doaj +5 more sources
TYROSINE KINASE INHIBITORS AND INTERFERON
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytine was the standard choice for treatment for
Maria Dimou, Panagiotis Panagiotidis
doaj +4 more sources
TYROSINE KINASE INHIBITORS AND PREGNANCY
Mediterranean Journal of Hematology and Infectious Diseases, 2014 The management of patients with chronic myeloid leukemia (CML) during pregnancy has became recently a matter of continuous debate. The introduction of the Tyrosine Kinase Inhibitors (TKIs) in clinical practice has dramatically changed the prognosis of ...
Elisabetta Abruzzese +3 more
doaj +5 more sources
Insulin receptor has tyrosine kinase activity toward Shc in rat liver [PDF]
Brazilian Journal of Medical and Biological Research, 1998 Insulin induces tyrosine phosphorylation of Shc in cell cultures and in insulin-sensitive tissues of the intact rat. However, the ability of insulin receptor (IR) tyrosine kinase to phosphorylate Shc has not been previously demonstrated.
E.V. Páez-Espinosa +3 more
doaj +3 more sources
Thoracic Cancer, 2021 Background T790M mutation causes resistance to tyrosine kinase inhibitors (TKIs) in approximately 49% of patients with epidermal growth receptor‐mutant non‐small cell lung cancer (NSCLC).
Tadashi Nishimura +12 more
doaj +1 more source
mTORC2 is a tyrosine kinase [PDF]
Cell Research, 2015 The mammalian target of rapamycin (mTOR), a protein kinase, is the centre of huge attention due to its importance in intracellular signaling and in health and disease. In their recent study, Yin et al. show that mTOR can regulate signaling through the insulin-like growth factor 1 receptor and that it possesses a new enzymatic activity - the ability to ...
Christopher G. Proud, Xuemin Wang
openaire +2 more sources
Tyrosine Kinase Receptors in Oncology [PDF]
International Journal of Molecular Sciences, 2020 Tyrosine kinase receptors (TKR) comprise more than 60 molecules that play an essential role in the molecular pathways, leading to cell survival and differentiation. Consequently, genetic alterations of TKRs may lead to tumorigenesis and, therefore, cancer development.
Jorge Esteban-Villarrubia +8 more
openaire +4 more sources
New England Journal of Medicine, 2001 BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment ...
B. Druker +10 more
semanticscholar +1 more source
Journal of Xenobiotics, 2023 Immune thrombocytopenic purpura (ITP) is an acquired antibody or cell-mediated platelet damage or decreased platelet production. Steroids, IV immunoglobulins (IVIG), and Rho-anti-D antibodies are the commonly used initial treatments for ITP.
Muhammad Ashar Ali +8 more
doaj +1 more source